Overview
- Consolidated net profit rose 80% year on year to about Rs 48 crore as revenue increased roughly 22% to around Rs 217 crore, with operating margin expanding to 33%.
- Thyrocare processed about 53 million tests in the quarter, led by roughly 24% growth in the pathology franchise, while reiterating a debt‑free profile with net cash exceeding Rs 190 crore.
- The board declared a second interim dividend of Rs 7 per share, with Oct. 24 set as the record date and a planned payout of about Rs 37.1 crore.
- Directors also approved a 2-for-1 bonus issue of equity shares, with the record date to be announced.
- The stock jumped as much as 16% to an intraday high near Rs 1,474, and all four covering analysts maintain buy ratings with a 12‑month consensus target around Rs 1,557.